This report was first published by Endpoints News. To see the original version, click here
The first two China-to-West licensing deals of the Chinese New Year have landed.
GSK will again return to the world’s most bustling biopharma dealmaking region with a two-siRNA pact with Frontier Biotechnologies for undisclosed immunological diseases.
您已阅读9%（340字），剩余91%（3277字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。